Literature DB >> 21609376

Bilirubin levels predict malignancy in patients with obstructive jaundice.

Giuseppe Garcea1, Wee Ngu, Christopher P Neal, Ashley R Dennison, David P Berry.   

Abstract

BACKGROUND: Differentiating between benign and malignant causes of obstructive jaundice can be challenging, even with the advanced imaging and endoscopic techniques currently available. In patients with obstructive jaundice, the predictive accuracy of bilirubin levels at presentation was examined in order to determine whether such data could be used to differentiate between malignant and benign disease.
METHODS: A total of 1,026 patients with obstructive jaundice were identified. Patients were divided into benign and malignant groups. The benign patients were subgrouped into those with choledocholithiasis and those with inflammatory strictures of the biliary tree. Bilirubin levels at presentation and other demographic data were obtained from case records.
RESULTS: Area under the curve (AUC) values for bilirubin as a predictor of malignancy were highly significant for all benign presentations and for those with benign biliary strictures (AUC: 0.8 for both groups; P < 0.001). A bilirubin level > 100 µmol/l was determined to provide the optimum sensitivity and specificity for malignancy in all patients and in those without choledocholithiasis (71.9% and 86.9%, 71.9% and 88.0%, respectively). The application of a bilirubin level > 250 µmol/l achieved specificities of 97.1% and 98.0% in each subgroup of patients, respectively.
CONCLUSIONS: In patients with obstructive jaundice, bilirubin levels in isolation represent an important tool for discriminating between benign and malignant underlying causes.
© 2011 International Hepato-Pancreato-Biliary Association.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21609376      PMCID: PMC3103100          DOI: 10.1111/j.1477-2574.2011.00312.x

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  17 in total

1.  Endoscopic ultrasound: a meta-analysis of test performance in suspected biliary obstruction.

Authors:  Donald Garrow; Scott Miller; Debajyoti Sinha; Jason Conway; Brenda J Hoffman; Robert H Hawes; Joseph Romagnuolo
Journal:  Clin Gastroenterol Hepatol       Date:  2007-05       Impact factor: 11.382

Review 2.  Spectrum of benign lesions mimicking a malignant stricture at the liver hilum.

Authors:  Woubet Tefera Kassahun; Sven Jonas
Journal:  Rev Recent Clin Trials       Date:  2009-09

3.  MRI combined with MR cholangiopancreatography versus helical CT in the evaluation of patients with suspected periampullary tumors: a prospective comparative study.

Authors:  M Andersson; S Kostic; M Johansson; L Lundell; M Asztély; M Hellström
Journal:  Acta Radiol       Date:  2005-02       Impact factor: 1.990

4.  Pancreaticoduodenectomies in patients without periampullary neoplasms: lesions that masquerade as cancer.

Authors:  Michael G Hurtuk; Margo Shoup; Kiyoko Oshima; Sherri Yong; Gerard V Aranha
Journal:  Am J Surg       Date:  2010-03       Impact factor: 2.565

5.  Pancreatic cancer detection with magnetic resonance cholangiopancreatography and endoscopic retrograde cholangiopancreatography: a prospective controlled study.

Authors:  H E Adamek; J Albert; H Breer; M Weitz; D Schilling; J F Riemann
Journal:  Lancet       Date:  2000-07-15       Impact factor: 79.321

6.  Differentiation between benign and malignant hilar obstructions using laboratory and radiological investigations: a prospective study.

Authors:  Sundeep Singh Saluja; Raju Sharma; Sujoy Pal; Peush Sahni; Tushar Kanti Chattopadhyay
Journal:  HPB (Oxford)       Date:  2007       Impact factor: 3.647

7.  CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions.

Authors:  Daniele Marrelli; Stefano Caruso; Corrado Pedrazzani; Alessandro Neri; Eduardo Fernandes; Mario Marini; Enrico Pinto; Franco Roviello
Journal:  Am J Surg       Date:  2009-04-17       Impact factor: 2.565

8.  Diagnostic impact of 18F-FDG PET-CT evaluating solid pancreatic lesions versus endosonography, endoscopic retrograde cholangio-pancreatography with intraductal ultrasonography and abdominal ultrasound.

Authors:  Verena Schick; Christiane Franzius; Torsten Beyna; May Lin Oei; Jürgen Schnekenburger; Matthias Weckesser; Wolfram Domschke; Otmar Schober; Walter Heindel; Thorsten Pohle; Kai Uwe Juergens
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-05-15       Impact factor: 9.236

9.  Elevation of carbohydrate antigen 19.9 in benign hepatobiliary conditions and its correlation with serum bilirubin concentration.

Authors:  S L Ong; A Sachdeva; G Garcea; G Gravante; M S Metcalfe; D M Lloyd; D P Berry; A R Dennison
Journal:  Dig Dis Sci       Date:  2008-05-09       Impact factor: 3.199

10.  Detection of serum MMP-7 and MMP-9 in cholangiocarcinoma patients: evaluation of diagnostic accuracy.

Authors:  Kawin Leelawat; Sompong Sakchinabut; Siriluck Narong; Jerasak Wannaprasert
Journal:  BMC Gastroenterol       Date:  2009-04-30       Impact factor: 3.067

View more
  13 in total

1.  Total bilirubin is a good discriminator between benign and malignant biliary strictures.

Authors:  Larisa Vasilieva; Alexandra Alexopoulou; Stephanos I Papadhimitriou; Andreas Romanos; Dimitrios Xynopoulos; Spyros P Dourakis
Journal:  HPB (Oxford)       Date:  2011-10-23       Impact factor: 3.647

2.  Evaluation of the American Society of Gastrointestinal Endoscopy 2019 and the European Society of Gastrointestinal Endoscopy guidelines' performances for choledocholithiasis prediction in clinically suspected patients: A retrospective cohort study.

Authors:  Suppadech Tunruttanakul; Borirak Chareonsil; Kotchakorn Verasmith; Jayanton Patumanond; Chatchai Mingmalairak
Journal:  JGH Open       Date:  2022-05-25

3.  Liver Cancer Study Group of Japan Clinical Practice Guidelines for Intrahepatic Cholangiocarcinoma.

Authors:  Shoji Kubo; Hiroji Shinkawa; Yoshinari Asaoka; Tatsuya Ioka; Hiroshi Igaki; Namiki Izumi; Takao Itoi; Michiaki Unno; Masayuki Ohtsuka; Takuji Okusaka; Masumi Kadoya; Masatoshi Kudo; Takashi Kumada; Norihiro Kokudo; Michiie Sakamoto; Yoshihiro Sakamoto; Hideyuki Sakurai; Tadatoshi Takayama; Osamu Nakashima; Yasushi Nagata; Etsuro Hatano; Kenichi Harada; Takamichi Murakami; Masakazu Yamamoto
Journal:  Liver Cancer       Date:  2022-02-23       Impact factor: 12.430

4.  Malignant biliary strictures in patients with a normal bilirubin and/or normal liver enzymes.

Authors:  Sarah C Thomasset; David Saunders; Adele Holland; Ashley R Dennison; Giuseppe Garcea
Journal:  HPB (Oxford)       Date:  2015-08-07       Impact factor: 3.647

5.  Surface-immobilized and self-shaped DNA hydrogels and their application in biosensing.

Authors:  Xiaoxia Mao; Guifang Chen; Zihan Wang; Yuanguang Zhang; Xiaoli Zhu; Genxi Li
Journal:  Chem Sci       Date:  2017-11-22       Impact factor: 9.825

6.  Differential diagnostic roles of the serum CA19-9, total bilirubin (TBIL) and the ratio of CA19-9 to TBIL for benign and malignant.

Authors:  Wei Liu; Qiaofei Liu; Wenqin Wang; Penghui Wang; Jieming Chen; Tao Hong; Ning Zhang; Binglu Li; Qiang Qu; Xiaodong He
Journal:  J Cancer       Date:  2018-04-19       Impact factor: 4.207

Review 7.  Early Diagnosis And Management Of Malignant Distal Biliary Obstruction: A Review On Current Recommendations And Guidelines.

Authors:  Michael Fernandez Y Viesca; Marianna Arvanitakis
Journal:  Clin Exp Gastroenterol       Date:  2019-11-05

8.  Radiographic Features and Clinical Factor for Preoperative Prediction in the Bulging Duodenal Papilla With Malignancy.

Authors:  Xiao-Jie Wang; Jun-Li Ke; Jian-Xia Xu; Jia-Ping Zhou; Yuan-Fei Lu; Qiao-Mei Zhou; Dan Shi; Ri-Sheng Yu
Journal:  Front Oncol       Date:  2021-04-01       Impact factor: 6.244

Review 9.  The Diagnostic Dilemma of Malignant Biliary Strictures.

Authors:  Robert Dorrell; Swati Pawa; Yi Zhou; Neeraj Lalwani; Rishi Pawa
Journal:  Diagnostics (Basel)       Date:  2020-05-25

Review 10.  Diagnostic Process Using Endoscopy for Biliary Strictures: A Narrative Review.

Authors:  Yuki Tanisaka; Masafumi Mizuide; Akashi Fujita; Tomoya Ogawa; Masahiro Suzuki; Hiromune Katsuda; Youichi Saito; Kazuya Miyaguchi; Tomoaki Tashima; Yumi Mashimo; Shomei Ryozawa
Journal:  J Clin Med       Date:  2021-03-03       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.